Clinical Trials Using Pralatrexate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Pralatrexate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-4 of 4
  • Pembrolizumab with Decitabine and / or Pralatrexate in Treating Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma

    This phase Ib trial studies the side effects and best dose of decitabine and pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma that have come back or do not respond to treatment. Drugs used in chemotherapy, such as pralatrexate and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab with decitabine and / or pralatrexate may work better in treating patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma.
    Location: 3 locations

  • Pralatrexate and Romidepsin in Treating Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma

    This phase I / IIa trial studies the side effects and the best dose of pralatrexate and romidepsin and to see how well they work in treating patients with lymphoma or multiple myeloma that has come back after a period of improvement or does not respond to treatment. Pralatrexate may slow, stop, or decrease the growth of cancer cells by blocking how cells are made. Romidepsin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pralatrexate together with romidepsin may work better in treating patients with non-Hodgkin's lymphoma, Hodgkin's lymphoma, or multiple myeloma
    Location: 3 locations

  • Pembrolizumab and Pralatrexate in Treating Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas

    This phase I / II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of improvement or has not responded to treatment. Pralatrexate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and pralatrexate may work better in treating patients with peripheral T-cell lymphomas.
    Location: 3 locations

  • Durvalumab, Pralatrexate, Romidepsin, and Oral Azacitidine in Treating Patients with Peripheral T-Cell Lymphoma

    This phase I and IIa trial studies the side effects and best dose of durvalumab, pralatrexate, romidepsin, and oral azacitidine, and to see how well they work in treating patients with peripheral T-cell lymphoma. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Pralatrexate is a chemotherapy drug that blocks how cells are made and therefore the growth of cancer cells can be slowed, stopped, or decreased. Romidepsin is another type of chemotherapy drug that helps stop the growth of cancer cells and can help kill cancer cells. Oral azacitidine prevents the body from making deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) that cells need to grow, which stops the growth of cancer cells and causes them to die. It is not yet known which combination of these drugs work best in treating patients with peripheral T-cell lymphoma.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York